Thyroid Cancer: Active Surveillance vs Surgery for Low-Risk Papillary

The Overtreatment Problem in Thyroid Cancer

The management of low-risk papillary thyroid cancer has undergone a paradigm shift: active surveillance is now an accepted alternative to immediate surgery for appropriately selected patients with papillary thyroid microcarcinomas. This represents a fundamental change in how clinicians and patients think about a cancer diagnosis — moving from reflexive surgical intervention to a risk-stratified approach that acknowledges that many small papillary thyroid cancers will never cause clinical harm. For the endocrinologist, surgeon, or primary care physician involved in thyroid nodule management, understanding the evidence supporting active surveillance and the criteria for patient selection is essential.

Thyroid cancer incidence has tripled over the past 30 years, driven almost entirely by detection of small papillary thyroid carcinomas (PTC) through increased imaging. Approximately 60% of newly diagnosed PTCs are microcarcinomas (1 cm or less), with disease-specific mortality below 1% at 20 years[1]. Autopsy studies reveal occult papillary microcarcinomas in 5-36% of individuals who died of unrelated causes[1], indicating that most of these tumors are indolent and clinically insignificant. This overdiagnosis, relevant to broader cancer screening discussions, has led to unnecessary surgery, with associated risks of hypoparathyroidism (1-6%), recurrent laryngeal nerve injury (1-2%), and lifelong thyroid hormone replacement[1].

The Kuma Hospital and Cancer Institute Hospital Experience

Kuma Hospital in Japan pioneered active surveillance for papillary microcarcinoma beginning in 1993[1]. In a cohort of 1,235 patients observed over a median of 5 years, tumor growth (3 mm or more increase) occurred in only 8% and lymph node metastasis in 3.8%[1]. Disease-specific survival was 100%[1]. The Cancer Institute Hospital Tokyo reported similar results: among 300 patients followed for a median of 6.5 years, 93% showed no progression. Critically, delayed surgery after active surveillance achieved identical disease-free survival compared to immediate surgery, confirming that a period of observation does not compromise oncologic outcomes.

Patient Selection for Active Surveillance

The 2024 ATA management guidelines (complementing thyroid nodule evaluation criteria) and international consensus support active surveillance for: papillary thyroid carcinoma 1 cm or less (some centers extending to 1.5 cm), no extrathyroidal extension on ultrasound, no lymph node metastasis on initial evaluation, no evidence of aggressive histologic variants (tall cell, hobnail, diffuse sclerosing), tumor not adjacent to the trachea or recurrent laryngeal nerve (minimum 2 mm margin), absence of BRAF V600E mutation with concurrent TERT promoter mutation (associated with aggressive behavior), patient willingness to comply with monitoring, and available experienced ultrasound surveillance. Age under 18 or patient anxiety rendering surveillance psychologically intolerable are relative contraindications.